Literature DB >> 19361030

Use of a thrombelastograph platelet mapping assay for diagnosis of clopidogrel resistance: a case report.

John Morton1, Satyanarayana Nelluri.   

Abstract

A 62-year-old woman presented to the emergency department with sudden collapse, intractable ventricular fibrillation, and an inferior wall myocardial infarction (MI). An emergent cardiac catheterization showed a totally occluded right coronary artery (RCA). A bare-metal stent was placed in the stenosis, resulting in thrombolysis in myocardial infarction (TIMI)-III flow with 0% residual stenosis. Four days after stenting, the patient developed chest pain. A repeat cardiac catheterization showed a totally occluded stent. The patient was subsequently tested using a thrombelastograph (TEG) Platelet Mapping assay to exclude clopidogrel resistance. The assay confirmed the patient to be non-responsive to clopidogrel for the inhibition of platelet ADP receptors. In an attempt to increase ADP inhibition, the ADP antagonist was changed to ticlopidine. Further testing was confounded by the presence of abciximab; however, the patient has remained free of cardiac events.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19361030      PMCID: PMC4680222     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  9 in total

1.  The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.

Authors:  Thomas A Clarke; Lucy A Waskell
Journal:  Drug Metab Dispos       Date:  2003-01       Impact factor: 3.922

2.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

Authors:  Steven R Steinhubl; Peter B Berger; J Tift Mann; Edward T A Fry; Augustin DeLago; Charles Wilmer; Eric J Topol
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

3.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

4.  Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome.

Authors:  D Mukherjee; E Kline-Rogers; J Fang; K Munir; K A Eagle
Journal:  Heart       Date:  2005-01       Impact factor: 5.994

5.  Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.

Authors:  S R Steinhubl; J D Talley; G A Braden; J E Tcheng; P J Casterella; D J Moliterno; F I Navetta; P B Berger; J J Popma; G Dangas; R Gallo; D C Sane; J F Saucedo; G Jia; A M Lincoff; P Theroux; D R Holmes; P S Teirstein; D J Kereiakes
Journal:  Circulation       Date:  2001-05-29       Impact factor: 29.690

6.  Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.

Authors:  John W Eikelboom; Jack Hirsh; Jeffrey I Weitz; Marilyn Johnston; Qilong Yi; Salim Yusuf
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

7.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

Review 8.  Antiplatelet drug resistance: not ready for prime time.

Authors:  Tammy L Burns; Aryan N Mooss; Daniel E Hilleman
Journal:  Pharmacotherapy       Date:  2005-11       Impact factor: 4.705

9.  Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.

Authors:  Shlomi Matetzky; Boris Shenkman; Victor Guetta; Michael Shechter; Roy Beinart; Roy Bienart; Ilan Goldenberg; Ilya Novikov; Hanna Pres; Naphtali Savion; David Varon; Hanoch Hod
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

  9 in total
  2 in total

1.  Monitoring the hemostasis with rotation thromboelastometry in patients with acute STEMI on dual antiplatelet therapy: First experiences.

Authors:  Matej Samoš; Lucia Stančiaková; Lukáš Duraj; František Kovář; Marián Fedor; Radoslava Šimonová; Tomáš Bolek; Peter Galajda; Ján Staško; Peter Kubisz; Marián Mokáň
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

Review 2.  Viscoelastic Hemostatic Assays and Platelet Function Testing in Patients with Atherosclerotic Vascular Diseases.

Authors:  Matej Samoš; Ingrid Škorňová; Tomáš Bolek; Lucia Stančiaková; Barbora Korpallová; Peter Galajda; Ján Staško; Peter Kubisz; Marián Mokáň
Journal:  Diagnostics (Basel)       Date:  2021-01-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.